查看購物車
  • Simplified Chinese
  • English
  • Japanese
A型血友病 A市場 - 全球和區域分析：按治療類型和區域 - 分析和預測（2025-2035 年）
市場調查報告書
商品編碼
1819724

A型血友病 A市場 - 全球和區域分析：按治療類型和區域 - 分析和預測（2025-2035 年）

Hemophilia A Market - A Global and Regional Analysis: Focus on Treatment Type, Country, and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5個工作天內

價格

全球A型血友病 A市場 - 分析與預測（2025-2035 年）

A型血友病 A是一種罕見的遺傳性疾病，其特徵是缺乏或缺乏血液凝固因子 VIII，而該因子對於血液凝固至關重要。

因此，A型血友病A患者即使輕微損傷也可能長時間或自發性出血。這種出血可能轉為內出血，並導致關節損傷和血尿等併發症。A型血友病A通常以X連鎖隱性遺傳方式遺傳，因此主要影響男性，女性通常是帶因者。治療通常需要定期輸注以補充缺失的凝血因子，但包括基因療法在內的新治療方法正在開發中，以提供更持久的解決方案。

A型血友病A市場的成長得益於治療方法的進步，這些進步顯著改善了患者的預後。傳統的凝血因子替代療法需要頻繁輸注，但半衰期延長的凝血因子降低了輸注頻率，提高了便利性。對於有抑制劑的患者，諸如艾美珠單抗（emicizumab）之類的非凝血因子替代療法提供了一種有效的替代方案，且給藥頻率更低。此外，基因療法已成為一種突破性的解決方案，透過解決導致A型血友病A的基因缺陷，有望提供長期甚至根治性的治療。

此外，隨著人們對A型血友病A的認知不斷提高，加之診斷技術的進步，人們可以更早發現病情，並更準確地診斷。醫療保健提供者和一般民眾的認知度不斷提高，使得更多患者能夠在早期得到診斷，這對於有效的管理和治療至關重要。早期診斷可以及時干預，預防關節損傷和過度出血等併發症，並改善患者的整體預後。人們對該疾病的認知不斷提高，促進了對專科治療的需求穩步成長，進一步擴大了市場。

儘管取得了這些進展，A型血友病 A市場仍面臨若干挑戰。其中之一就是A型血友病 A治療費用高。雖然傳統的因子替代療法已經問世多年，但延長半衰期的凝血因子和基因療法等較新的治療方法卻要昂貴得多。例如，基因療法每次治療的費用可能高達數十萬美元。雖然延長半衰期療法可以減少輸液次數，但它們比標準療法更昂貴。這些高昂的費用給醫療保健系統和患者都帶來了經濟負擔，尤其是在資源有限的地區。這種負擔能力問題限制了許多患者獲得這些先進治療方法的機會，尤其是那些醫療保健基礎設施和保險覆蓋不足或缺乏的中低收入國家的患者。

另一個挑戰是監管挑戰和核准延遲。新治療方法，尤其是基因療法，面臨重大的監管障礙。開發和核准創新治療方法需要漫長而昂貴的臨床試驗以及足夠的安全性和有效性證據。完成這些臨床試驗可能需要數年時間，減緩了新治療方法的推出。此外，不同的區域監管機構（例如美國的FDA和歐洲的EMA）有不同的核准流程和時間表，從而延遲了新治療方法在全球的採用。這種監管複雜性減緩了新治療方法在全球的推出，限制了患者及時獲得治療，並阻礙了市場成長。

全球A型血友病 A市場競爭激烈，Alnylam Pharmaceuticals、輝瑞公司、羅氏公司、諾和諾德公司和武田製藥等主要企業推動創新和市場成長。這些公司在開發可顯著改善患者預後的新治療方法處於領先地位。透過對研發 (R&D) 的策略性投資、擴大產品系列以及增加全球獲得最先進治療的機會，這些行業領導者正在塑造A型血友病 A治療的未來並為市場動態成長做出貢獻。此外，擴展到新興市場並透過區域分銷網路加強其影響力是挖掘服務不足的患者群體的關鍵策略。這些策略使公司能夠加強其市場地位並加速競爭激烈的A型血友病 A治療市場中的成長。

A型血友病A市場細分

細分1：按地區

  • 北美洲
  • 歐洲
  • 亞太地區

隨著診斷技術的進步，A型血友病A的檢測越來越準確，也越來越早。在已開發國家，新生兒篩檢和基因檢測可以實現更早的發現，從而提高了確診病例的盛行率。檢出率的提高，加上醫療保健提供者和公眾意識的增強，正在推動治療需求。世界血友病聯盟 (WFH) 等倡導組織在傳播A型血友病A的認知和早期療育的重要性方面發揮關鍵作用，這進一步推動了治療需求。

目錄

執行摘要

第1章全球A型血友病 A市場：產業分析

  • 市場概況與生態系統
  • 流行病學分析
  • 主要市場趨勢
    • 影響分析
  • 監管狀況
  • 管道分析
  • 市場動態
    • 概述
    • 市場促進因素
    • 市場限制
    • 市場機遇

2. 全球A型血友病 A市場（依治療類型）價值，2023-2035 年

  • 因子替代療法
  • 非因子替代療法
  • 基因治療

3. 全球A型血友病 A市場（按地區）價值，2023-2035 年

  • 北美洲
  • 歐洲
  • 亞太地區

第4章 競爭格局與公司概況

  • 競爭格局
  • 公司簡介
    • Alnylam Pharmaceuticals
    • Pfizer Inc.
    • HEMA Biologics
    • F. Hoffmann-La Roche Ltd.
    • Chugai Pharmaceutical Co., Ltd.
    • BioMarin Pharmaceutical
    • Novo Nordisk A/S
    • LFB
    • Octapharma
    • Bayer Vital GmbH
    • Takeda Pharmaceutical
    • CSL Behring
    • Ultragenyx Pharmaceutical
    • Sangamo Therapeutics
    • ASC Therapeutics
    • 其他

第5章調查方法

Product Code: BHL3267SA

Global Hemophilia A Market, Analysis and Forecast: 2025-2035

Hemophilia A is a rare genetic disorder characterized by a deficiency or absence of clotting factor VIII, which is essential for blood clotting. As a result, individuals with Hemophilia A experience prolonged or spontaneous bleeding, even from minor injuries. This bleeding can occur internally, leading to joint damage or complications like hemarthrosis. Hemophilia A is typically inherited in an X-linked recessive pattern, meaning it primarily affects males, while females are usually carriers. Treatment usually involves replacing the missing clotting factor through regular infusions, and newer therapies, including gene therapy, are being developed to offer more lasting solutions.

The growth of the hemophilia A market is driven by advancements in treatment options that have significantly improved patient outcomes. Traditionally, factor replacement therapy required frequent infusions, but extended half-life clotting factors have reduced infusion frequency, improving convenience. For patients with inhibitors, non-factor replacement therapies like Emicizumab offer an effective alternative with less frequent dosing. Additionally, gene therapy has emerged as a groundbreaking solution, potentially offering long-term or curative treatment by addressing the genetic defect causing Hemophilia A. These innovations provide more effective, flexible, and long-lasting treatments, enhancing patient care and driving market growth.

Additionally, rising awareness of hemophilia A, coupled with improved diagnostic techniques, has led to earlier detection and more accurate diagnoses. Better awareness among both healthcare providers and the general population has resulted in more individuals being diagnosed at an earlier stage, which is critical for effective management and treatment. Early diagnosis allows for timely interventions, which help prevent complications, such as joint damage and excessive bleeding episodes, and improve overall patient outcomes. This growing recognition of the condition has contributed to a steady increase in demand for specialized therapies, expanding the market further.

Despite these advances, the hemophilia A market faces several challenges. One significant hurdle is the high treatment costs of hemophilia A. While traditional factor replacement therapies have been around for years, new treatments such as extended half-life clotting factors and gene therapies come with a much higher price tag. For instance, gene therapies can cost hundreds of thousands of dollars for a single treatment. Extended half-life products, while reducing the frequency of infusions, are also more expensive than standard therapies. These high costs present a financial burden for both healthcare systems and patients, particularly in regions with limited resources. This pricing issue limits the accessibility of these advanced therapies to many patients, especially those in low- and middle-income countries, where healthcare infrastructure and insurance coverage may be inadequate or lacking.

Another challenge is the regulatory challenges and approval delays. New therapies, particularly gene therapies, face significant regulatory hurdles. Developing and gaining approval for innovative treatments requires long, expensive clinical trials and substantial evidence of safety and efficacy. These trials can take years to complete, slowing the rollout of new therapies. Additionally, regulatory agencies in different regions such as the FDA in the U.S. and EMA in Europe have varying approval processes and timelines, causing delays in making new treatments available globally. These regulatory complexities slow down the global rollout of new therapies, limiting their timely access to patients and hindering market growth.

The global hemophilia A market is highly competitive, with several leading companies driving innovation and market growth, such as Alnylam Pharmaceuticals, Pfizer Inc., F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, Takeda Pharmaceutical. These companies are at the forefront of developing novel therapies that are significantly improving patient outcomes. Through strategic investments in research and development (R&D), expanding product portfolios, and increasing global access to cutting-edge treatments, these industry leaders are shaping the future of hemophilia A care and contributing to the dynamic growth of the market. Additionally, expanding into emerging markets and increasing their presence through regional distribution networks are key strategies to tap into underserved patient populations. These strategies are enabling companies to strengthen their market position and accelerate growth in the competitive hemophilia A treatment landscape.

Hemophilia A Market Segmentation:

Segmentation 1: by Region

  • North America
  • Europe
  • Asia-Pacific

As diagnostic technologies improve, the detection of hemophilia A has become more accurate and early. In developed countries, newborn screening and genetic testing allow for early identification, which increases the prevalence of diagnosed cases. This higher detection rate, along with greater awareness among both healthcare providers and the public, drives the demand for treatments. Advocacy groups, such as the World Federation of Hemophilia (WFH), play a crucial role in spreading awareness about hemophilia A and the importance of early intervention, which further drives the demand for therapies.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Hemophilia A Market: Industry Analysis

  • 1.1 Market Overview and Ecosystem
  • 1.2 Epidemiological Analysis
  • 1.3 Key Market Trends
    • 1.3.1 Impact Analysis
  • 1.4 Regulatory Landscape
  • 1.5 Pipeline Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Overview
    • 1.6.2 Market Drivers
    • 1.6.3 Market Restraints
    • 1.6.4 Market Opportunities

2. Global Hemophilia A Market (by Treatment Type), Value ($Million), 2023-2035

  • 2.1 Factor Replacement Therapies
  • 2.2 Non-Factor Replacement Therapies
  • 2.3 Gene Therapies

3. Global Hemophilia A Market (by Region), Value ($Million), 2023-2035

  • 3.1 North America
    • 3.1.1 Market Dynamics
    • 3.1.2 Market Sizing and Forecast
    • 3.1.3 North America Hemophilia A Market, by Country ($Million), 2023-2035
      • 3.1.3.1 U.S.
  • 3.2 Europe
    • 3.2.1 Market Dynamics
    • 3.2.2 Market Sizing and Forecast
    • 3.2.3 Europe Hemophilia A Market, by Country ($Million), 2023-2035
      • 3.2.3.1 U.K.
      • 3.2.3.2 France
      • 3.2.3.3 Germany
      • 3.2.3.4 Italy
      • 3.2.3.5 Spain
  • 3.3 Asia-Pacific
    • 3.3.1 Market Dynamics
    • 3.3.2 Market Sizing and Forecast
    • 3.3.3 Asia-Pacific Hemophilia A Market, by Country ($Million), 2023-2035
      • 3.3.3.1 Japan

4. Competitive Landscape and Company Profiles

  • 4.1 Competitive Landscape
    • 4.1.1 Mergers and Acquisitions
    • 4.1.2 Partnership, Alliances and Business Expansion
    • 4.1.3 New Offerings
    • 4.1.4 Regulatory Activities
    • 4.1.5 Funding Activities
  • 4.2 Company Profiles
    • 4.2.1 Alnylam Pharmaceuticals.
      • 4.2.1.1 Overview
      • 4.2.1.2 Top Products / Product Portfolio
      • 4.2.1.3 Top Competitors
      • 4.2.1.4 Target Customers/End-Users
      • 4.2.1.5 Key Personnel
      • 4.2.1.6 Analyst View
    • 4.2.2 Pfizer Inc.
      • 4.2.2.1 Overview
      • 4.2.2.2 Top Products / Product Portfolio
      • 4.2.2.3 Top Competitors
      • 4.2.2.4 Target Customers/End-Users
      • 4.2.2.5 Key Personnel
      • 4.2.2.6 Analyst View
    • 4.2.3 HEMA Biologics.
      • 4.2.3.1 Overview
      • 4.2.3.2 Top Products / Product Portfolio
      • 4.2.3.3 Top Competitors
      • 4.2.3.4 Target Customers/End-Users
      • 4.2.3.5 Key Personnel
      • 4.2.3.6 Analyst View
    • 4.2.4 F. Hoffmann-La Roche Ltd.
      • 4.2.4.1 Overview
      • 4.2.4.2 Top Products / Product Portfolio
      • 4.2.4.3 Top Competitors
      • 4.2.4.4 Target Customers/End-Users
      • 4.2.4.5 Key Personnel
      • 4.2.4.6 Analyst View
    • 4.2.5 Chugai Pharmaceutical Co., Ltd.
      • 4.2.5.1 Overview
      • 4.2.5.2 Top Products / Product Portfolio
      • 4.2.5.3 Top Competitors
      • 4.2.5.4 Target Customers/End-Users
      • 4.2.5.5 Key Personnel
      • 4.2.5.6 Analyst View
    • 4.2.6 BioMarin Pharmaceutical.
      • 4.2.6.1 Overview
      • 4.2.6.2 Top Products / Product Portfolio
      • 4.2.6.3 Top Competitors
      • 4.2.6.4 Target Customers/End-Users
      • 4.2.6.5 Key Personnel
      • 4.2.6.6 Analyst View
    • 4.2.7 Novo Nordisk A/S.
      • 4.2.7.1 Overview
      • 4.2.7.2 Top Products / Product Portfolio
      • 4.2.7.3 Top Competitors
      • 4.2.7.4 Target Customers/End-Users
      • 4.2.7.5 Key Personnel
      • 4.2.7.6 Analyst View
    • 4.2.8 LFB.
      • 4.2.8.1 Overview
      • 4.2.8.2 Top Products / Product Portfolio
      • 4.2.8.3 Top Competitors
      • 4.2.8.4 Target Customers/End-Users
      • 4.2.8.5 Key Personnel
      • 4.2.8.6 Analyst View
    • 4.2.9 Octapharma.
      • 4.2.9.1 Overview
      • 4.2.9.2 Top Products / Product Portfolio
      • 4.2.9.3 Top Competitors
      • 4.2.9.4 Target Customers/End-Users
      • 4.2.9.5 Key Personnel
      • 4.2.9.6 Analyst View
    • 4.2.10 Bayer Vital GmbH.
      • 4.2.10.1 Overview
      • 4.2.10.2 Top Products / Product Portfolio
      • 4.2.10.3 Top Competitors
      • 4.2.10.4 Target Customers/End-Users
      • 4.2.10.5 Key Personnel
      • 4.2.10.6 Analyst View
    • 4.2.11 Takeda Pharmaceutical.
      • 4.2.11.1 Overview
      • 4.2.11.2 Top Products / Product Portfolio
      • 4.2.11.3 Top Competitors
      • 4.2.11.4 Target Customers/End-Users
      • 4.2.11.5 Key Personnel
      • 4.2.11.6 Analyst View
    • 4.2.12 CSL Behring.
      • 4.2.12.1 Overview
      • 4.2.12.2 Top Products / Product Portfolio
      • 4.2.12.3 Top Competitors
      • 4.2.12.4 Target Customers/End-Users
      • 4.2.12.5 Key Personnel
      • 4.2.12.6 Analyst View
    • 4.2.13 Ultragenyx Pharmaceutical.
      • 4.2.13.1 Overview
      • 4.2.13.2 Top Products / Product Portfolio
      • 4.2.13.3 Top Competitors
      • 4.2.13.4 Target Customers/End-Users
      • 4.2.13.5 Key Personnel
      • 4.2.13.6 Analyst View
    • 4.2.14 Sangamo Therapeutics.
      • 4.2.14.1 Overview
      • 4.2.14.2 Top Products / Product Portfolio
      • 4.2.14.3 Top Competitors
      • 4.2.14.4 Target Customers/End-Users
      • 4.2.14.5 Key Personnel
      • 4.2.14.6 Analyst View
    • 4.2.15 ASC Therapeutics.
      • 4.2.15.1 Overview
      • 4.2.15.2 Top Products / Product Portfolio
      • 4.2.15.3 Top Competitors
      • 4.2.15.4 Target Customers/End-Users
      • 4.2.15.5 Key Personnel
      • 4.2.15.6 Analyst View
    • 4.2.16 Others

5. Research Methodology

List of Figures

  • Figure: Global Hemophilia A Market Coverage
  • Figure: Global Hemophilia A Market Key Trends, Impact Analysis, 2023-2035

List of Tables

  • Table: Global Hemophilia A Market Dynamics, Impact Analysis
  • Table: Global Hemophilia A Market (by Treatment Type), $Million, 2023-2035
  • Table: Global Hemophilia A Market (by Region), $Million, 2023-2035